- active not recruitingPHASE2
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
This study looks at new cancer vaccines, SCIB1 and iSCIB1+, for advanced skin cancer (melanoma). They are being tested with standard treatments (nivolumab/ipilimumab or pembrolizumab) to see if they are safe and can help these treatments work better or for longer.
United Kingdom - active not recruitingPHASE2
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
This study looks at using a new blood test to help decide when to give a drug called tebentafusp to people with certain types of melanoma that have been treated but could come back. The aim is to see if tebentafusp can help them live longer.
United Kingdom - recruiting
French Clinical Datbase of Melanoma Patients (RIC-Mel)
This study in France gathers information from melanoma patients to create a large database. It helps researchers better understand melanoma and improve treatments. The goal is to speed up research and clinical trials for this type of skin cancer, ultimately helping patients.
France - active not recruitingNA
MoleGazer Development Feasibility Study
This study is developing a new AI tool, 'MoleGazer', to help doctors track moles and spot skin cancer earlier. By comparing photos of your skin over time, it aims to find new or changing moles more easily. It's like how astrophysicists find new stars.
United Kingdom - recruitingNA
Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors
This study looks at how immune system chemicals (cytokines) change during treatment for advanced skin cancer (melanoma) with special drugs called checkpoint inhibitors. We want to see if these changes can predict how well the treatment works and if it will cause side effects.
France